electroCore, Inc.
electrocore.comelectroCore, Inc. (NASDAQ: ECOR) is a bioelectronic medicine company that develops and commercializes non-invasive vagus nerve stimulation therapy devices for medical and consumer wellness applications. Revenue comes from sales of prescription medical devices and direct-to-consumer wellness products, including the Truvaga app-enabled consumer product. The company competes in the neuromodulation device market against larger pharmaceutical and medical device companies, as well as dedicated neuromodulation competitors including Cefaly, Nerivo, and Savi Dual, all of which hold approvals for migraine treatment or prevention. electroCore is headquartered in Rockaway, New Jersey, where it maintains approximately 22,557 square feet of office, warehouse, and assembly space under a lease expiring July 31, 2034. The company has a history of significant losses and, as of the 10-K filed March 19, 2026, had not achieved sustained profitability or positive cash flow from operations.
Products & Services
Non-invasive vagus nerve stimulation devices for medical indications including chronic pain and migraine treatment or prevention. Consumer wellness product: Truvaga, with a next-generation app-enabled version referenced as in development as of the filing date.
Revenue Model
Product sales of prescription neuromodulation devices and direct-to-consumer wellness products, including the Truvaga app-enabled consumer device. No subscription or royalty revenue structure is described in the filing excerpts.
Customers & Markets
Patients and consumers in chronic pain and migraine end markets. Customers include physicians and direct-to-consumer buyers. The filing notes that some customers may treat products as discretionary purchases.
Geographic Exposure
Primary operations in the United States, headquartered in Rockaway, New Jersey. The filing references operating in multiple countries but does not specify revenue by geography in the excerpts provided.
Financial Snapshot
Loading...
